Comparison of Total Prostate-Specific Antigen and Derivative Levels in a Screening Population of Black, White, and Korean-American Men

Clinical Prostate Cancer

Volumn 2, Issue 3, 2003, Pages 173-176

  Park, Jae ^a   Sokoll, Lori J ^a   Bruzek, Debra J ^a   Mangold, Leslie ^a   Gurganus, Robin ^a   Khan, Masood A ^a   Partin, Alan W ^a   Chan, Daniel W ^a   Veltri, Robert W ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenocarcinoma; Detection; Ethnicity; PSA molecular forms; Race

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AFRICAN AMERICAN; AGED; ANALYSIS OF VARIANCE; ANTIGEN DETECTION; ARTICLE; BLOOD SAMPLING; CANCER SCREENING; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DISEASE MARKER; ETHNIC GROUP; HUMAN; KOREA; KRUSKAL WALLIS TEST; MALE; METHODOLOGY; NORMAL HUMAN; PROSTATE CANCER; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RACE DIFFERENCE; STATISTICAL ANALYSIS;

EID: 0348225313     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2003.n.026     Document Type: Article

References (20)

1. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J Urol 1999; 162:293-306.
2. Catalona WJ, Richie JP, Ahmenn FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151:1283-1290.
3. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 1993; 270:860-864.
4. Carroll PR. Serum prostate-specific antigen for prostate cancer early detection: total, free, age-stratified, or complexed? Urology 2001; 57:591-593.
5. Seaman E, Whang M, Olsson CA, et al. PSA density (PSAD): role in patient evaluation and management. Urol Clin North Am 1993; 20:653-663.
6. Catalona WJ, Smith DS, Wolfert RL, et al. Evaluation of percentage of free prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274:1214-1220.
7. Allard WJ, Zhou Z, Yeung KK. Novel measurement of complex prostate-specific antigen in serum. Clin Chem 1998; 44:1216-1223.
8. Brawer MK, Cheli CD, Neaman IE, et al. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol 2000; 163:1476-1480.
9. Miller MC, O'Dowd GJ, Partin AW, et al. Contemporary use of complexed PSA and calculated free PSA for early detection of prostate cancer: impact of changing disease demographics. Urology 2001; 57:1105-1111.
10. Veltri RW, Miller MC, O'Dowd GJ, et al. Impact of age on total and complexed PSA cut-offs in a contemporary referral series of men with prostate cancer. Urology 2002; 60(suppl 4A):47-52.
11. Catalona WJ, Hudson MA, Scardino PT, et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994; 152:2037-2042.
12. Morgan TO, Jacobson SJ, McCarthy WF, et al. Age-specific reference ranges for serum prostate-specific antigen in black men. N Engl J Med 1996; 335:304-310.
13. Lee C, Lee ES, Choi H, et al. Incidence of genitourinary cancer in Korea. J Kor Med Sci 1992; 7:154-161.
14. Hsing AW, Devesa SS. Trends and patterns in prostate cancer incidence and mortality. What do they suggest? Epidemiol Rev 2001; 23:3-13.
15. Kuwahara M, Tatsuo T, Kawamura S, et al. Mass screening for prostate cancer: a comparative study in Natori, Japan and Changchun, China. Urology 2003; 61:137-141.
16. Ku JH, Ahn JO, Lee CH, et al. Distribution of serum prostate-specific antigen in healthy Korean men: influence of ethnicity. Urology 2002; 60:475-479.
17. Egawa S, Suyama K, Takashima R, et al. Probability of prostate cancer at various levels of percent free prostate specific antigen in Japanese men with total PSA of 4.1-10.0 ng/ml. Prostate Cancer Prostatic Dis 2002; 5:115-118.
18. Mikolajczyk SD, Marks LS, Partin AW, et al. Free prostate-specific antigen in serum is becoming more complex. Urology 2002; 59:797-802.
19. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from the U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002; 94:981-990.
20. Carter HB, Walsh PC, Landis P, et al. Expectant management of non-palpable prostate cancer with curative intent: preliminary results. J Urol 2002; 167:1231-1234.